CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 100 target
Drug / intervention
Combination of three inhibitors Trametinib, Everolimus and Lenvatinibdrug
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Recurrent or refractory advanced solid tumors
  • ✓Age 18-85 years
  • ✓Life expectancy greater than 3 months
Key exclusion· 3
  • ✕Benign tumor
  • ✕Life expectancy less than 3 months
  • ✕Serious medical comorbidities

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04803318
NCT04803318Phase 2RecruitingOn TrackUpdated 24mo ago
Long Recruiting
CompareCT.gov

Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical Trial

Second Affiliated Hospital of Guangzhou Medical University·interventional·Posted Mar 17, 2021·Updated Jun 25, 2024

In Brief

A Phase 2 clinical trial evaluating Combination of three inhibitors Trametinib, Everolimus and Lenvatinib for Solid Tumor, Adult and Hepatocellular Carcinoma. Currently recruiting, targeting 100 participants across 1 site.

Detailed Summary

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Adult, Hepatocellular Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
20212022202320242025202620272028202920302031203220332034203520362037
First PostedMar 17, 2021
Enrollment StartJan 1, 2021
Primary CompletionJan 1, 2029
Study CompletionJan 1, 2037
TodayJul 1, 2026
Enrollment to primary: 8 yearsPosted 5.3 years agoPrimary completion in 2.5 years

Interventions

Combination of three inhibitors Trametinib, Everolimus and Lenvatinibdrug

Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.